open access

Vol 27, No 5 (2020)
Research letter — Clinical cardiology
Published online: 2020-08-07
Get Citation

First experience with sodium-glucose co-transporter 2 inhibitors in Polish patients with cardiovascular diseases

Ewa Dziewięcka, Mateusz Winiarczyk, Matylda Gliniak, Monika Kaciczak, Sylwia Wiśniowska-Śmiałek, Aleksandra Karabinowska, Katarzyna Holcman, Magdalena Kostkiewicz, Marta Hlawaty, Agata Leśniak-Sobelga, Piotr Podolec, Paweł Rubiś
DOI: 10.5603/CJ.a2020.0100
·
Pubmed: 32789840
·
Cardiol J 2020;27(5):639-641.

open access

Vol 27, No 5 (2020)
Research letter — Clinical cardiology
Published online: 2020-08-07

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

First experience with sodium-glucose co-transporter 2 inhibitors in Polish patients with cardiovascular diseases

Journal

Cardiology Journal

Issue

Vol 27, No 5 (2020)

Pages

639-641

Published online

2020-08-07

DOI

10.5603/CJ.a2020.0100

Pubmed

32789840

Bibliographic record

Cardiol J 2020;27(5):639-641.

Authors

Ewa Dziewięcka
Mateusz Winiarczyk
Matylda Gliniak
Monika Kaciczak
Sylwia Wiśniowska-Śmiałek
Aleksandra Karabinowska
Katarzyna Holcman
Magdalena Kostkiewicz
Marta Hlawaty
Agata Leśniak-Sobelga
Piotr Podolec
Paweł Rubiś

References (10)
  1. Lenzen M, Ryden L, Ohrvik J, et al. Euro Heart Survey Investigators. Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. Eur Heart J. 2006; 27(24): 2969–2974.
  2. Gasior M, Pres D, Stasik-Pres G, et al. Effect of blood glucose levels on prognosis in acute myocardial infarction in patients with and without diabetes, undergoing percutaneous coronary intervention. Cardiol J. 2008; 15(5): 422–430.
  3. Cosentino F, Grant PJ, Aboyans V, et al. ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020; 41(2): 255–323.
  4. Kralev S, Krause B, Papavassiliu T, et al. Clinical outcome of patients with diabetes presenting with ST-elevation myocardial infarction and treated with concomitant use of glycoprotein IIb/IIIa inhibitors. Cardiol J. 2009; 16(3): 234–240.
  5. Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22): 2117–2128.
  6. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380(19): 1880–1882.
  7. Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016; 37(19): 1526–1534.
  8. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020; 382(10): 972–973.
  9. Di Angelantonio E, Kaptoge S, Wormser D, et al. Association of cardiometabolic multimorbidity with mortality. JAMA. 2015; 314(1): 52–60.
  10. Sharma A, Zhao X, Hammill B, et al. Trends in noncardiovascular comorbidities among patients hospitalized for heart failure. Circ Hear Fail. 2018; 11(6).

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl